From: Imaging for Dupuytren disease: a systematic review of the literature
Study (year) | Design | Level of evidence | Imaging modality | N (hands) | Clinical details | Outcome parameters | Results | Additional value MRI | Additional value US |
---|---|---|---|---|---|---|---|---|---|
Christie (2011) [36] | Case-report | 5 | US | 1 (1) | A 42-year-old patient undergoing cross-frictional therapy (8 weeks) | - Visible changes: US + clinical examination - ROM - Symptoms (subjective) | - US: no observed subcutaneous changes - Clinical examination: decreased nodule size, skin wrinkling and contractile bands - Increased ROM - Reduced patient-reported symptoms | – | No |
Yin (2016) [37] | Prospective cohort study | 3 | US | 37 (49) | Dupuytren patients undergoing injection of triamcinolone acetonide in nodules. Follow-up: 5 years. | - Nodule size on US - Complications | - nodule size: reduction of 40% at 6 months and 56% at 5 years. - complications: none | – | Yes |
Banks (2017) [38] | Retrospective cohort study | 4 | MRI | 6 (8) | Patients with superficial fibromatoses of the hand and feet undergoing EBT Follow-up 4.5 months. | - Nodule volume on MRI - MRI signal intensity - Pain (VAS-score) | - Volume: significant decrease from 1.5 to 1.2 cm3 - Signal intensity: significant decrease - Pain: decrease in VAS-score in patients with high pre-treatment signal intensity | Yes | – |
Strömberg (2017) [39] | Prospective cohort study | 3 | US | 39 | 19 patients undergoing CCH, 20 patients undergoing PNF. Follow-up 1 year. | - Gap-width measured with US - Correction of MCP-joint - Recurrence | - Gap-width (median) 18 mm for both groups - MCP-correction (median): PNF 46° and CCH 53° - Recurrence: n = 1 | Yes |  |
Crivello (2015) [40] | Prospective cohort study | 4 | MRI | 5 (5) | 5 DD patients undergoing CCH in 5 fingers. Follow-up 30 days. | - MRI signal intensity - Cord volume | - MRI signal intensity: significant increase (320%) - Cord volume: significant decrease (72%) | Yes |  |